文献速递骨质疏松与钙磷/甲状旁腺

布罗索单抗对X连锁低磷性佝偻病患儿生长的真实世界影响

Real-world impact of treatment on growth in children with X-linked hypophosphatemia.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

基于3项真实世界观察性研究(APEX)的641例2–17岁X连锁低磷性佝偻病(XLH)患儿数据,比较布罗索单抗治疗与未治疗者的身高与生长情况。布罗索单抗组生长速度优于未治疗组(儿童每年增加0.085 Z评分,P<.0001;青少年每年增加0.121 Z评分,P<.0001),模型预测其成年身高更高。

要点

  • 布罗索单抗治疗与XLH患儿生长速度改善相关。
  • 儿童与青少年均见生长改善,模型预测成年身高更高。
  • 随访中位3.3年,为真实世界长期数据提供参考。

核心结论

  • 布罗索单抗与XLH儿童及青少年生长结局改善呈稳健正相关,模型预测可支持成年身高改善。

研究设计与样本

  • 3项正在进行的真实世界观察性研究(NCT03651505、NCT03193476、NCT03745521)统一为APEX研究;共分析641例2–17岁XLH患儿(女性402例),其中498例接受布罗索单抗、143例未接受;采用混合回归模型分别分析儿童与青少年。

主要发现

  • 布罗索单抗组较未治疗组生长速度提高:儿童每年增加0.085 Z评分(P<.0001),青少年每年增加0.121 Z评分(P<.0001)。
  • 模型预测布罗索单抗治疗者成年身高更高。
  • 入组年龄中位数(IQR):布罗索单抗组8(5–12)岁,未治疗组10(4–14)岁。

关键数值与推荐

  • 干预为皮下注射布罗索单抗,对照为口服磷酸盐联合活性维生素D或不治疗。
  • 随访中位3.3年,基于此建模预测成年身高。

临床怎么用

  • 在真实世界中,布罗索单抗可用于改善XLH患儿生长,尤其需长期随访身高与生长速度。
  • 对儿童和青少年均应关注治疗对成年身高的潜在获益。

局限性

  • 为观察性研究的中期数据,非随机对照,存在混杂可能。
  • 成年身高为模型预测而非实测终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: X-linked hypophosphatemia (XLH) is a rare, genetic, progressive, lifelong disorder manifest by impaired growth and disproportionate short stature. Burosumab, a monoclonal antibody against fibroblast growth factor 23, is approved for treating patients with XLH. OBJECTIVE: To understand the impact of burosumab treatment on growth in a real-world setting. DESIGN: Interim data from 3 ongoing, real-world observational studies (NCT03651505, NCT03193476, and NCT03745521), were unified into a single study (APEX). SETTING: Outpatient clinics. PATIENTS: Children aged 2-17 years with XLH. INTERVENTION(S): Subcutaneous burosumab vs oral phosphate salts and active vitamin D or no treatment. MAIN OUTCOME MEASURE(S): Retrospective and prospective height data from children enrolled in APEX were analyzed to provide long-term estimation of the impact of treatment on growth. Growth and height were estimated by a mixed regression model with separate models for children and adolescents. RESULTS: In total, 641 participants were analyzed (402 female) with 498 burosumab-treated and 143 burosumab naïve. Median (interquartile range [IQR]) enrollment ages were 8 (5-12) years for burosumab-treated and 10 (4-14) years for burosumab-naïve participants. Burosumab-treated participants experienced improved growth over burosumab-naïve participants (additional growth velocity: 0.085 Z-score/year for children [P < .0001]; 0.121 Z-score/year for adolescents [P < .0001]). Modeling predicted greater adult height among burosumab-treated participants. CONCLUSION: Burosumab had a robust, positive association with improved growth outcomes in male and female children and adolescents with XLH. Modeling based on a median of 3.3 years of follow-up predicted burosumab can support improvement of growth that will likely result in greater adult height.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fukumoto S, Haffner D, Imel EA, et al. Real-world impact of treatment on growth in children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2026. PMID: 41911946. doi:10.1210/clinem/dgag136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。